LLY Becomes "Dominant" GLP-1 Winner, NVO Growth Turns Anemic

We're back on Morning Trade Live. Let's take a closer look at the weight loss drug trade. Nova Nordisk and Eli Liy have gone in opposite directions over the last 12 months with Lily gaining market share in the GLP1 space and Nova Nordisk are undergoing some changes in the seauite.Novo is down more than 45% year-over-year while Lily is trading 9% off its all-time highs after a strong earnings report. All right, quite a conver divergence there, I should say. I'm getting those words mixed up this morning, but ...